YahooSeptember 1, 2026 at 8:15 AM NY3 days ago

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story